Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 211-222

  Tolcher, Anthony W ^a   Ochoa, Leonel ^a   Hammond, Lisa A ^a   Patnaik, Amita ^a   Edwards, Tam ^a   Takimoto, Chris ^a   Smith, Lon ^a   De Bono, Johann ^a   Schwartz, Garry ^a   Mays, Theresa ^a   Jonak, Zdenka L ^a   Johnson, Randall ^a   DeWitte, Mark ^a   Martino, Helen ^a   Audette, Charlene ^a   Maes, Kate ^a   Chari, Ravi V J ^a   Lambert, John M ^a   Rowinsky, Eric K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CANTUZUMAB MERTANSINE; MAYTANSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C242; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; FATIGUE; HUMAN; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; VOMITING; ADULT; AGED; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; HALF LIFE TIME; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CA-15-3 ANTIGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; IMMUNOCONJUGATES; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MAYTANSINE; MIDDLE AGED; NEOPLASMS;

EID: 0037440038     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.137     Document Type: Article

References (23)

1. Lambert J, DeWitte M, Martino HK, et al: SB-408075 Investigator Brochure. Collegeville, PA, SmithKline Beecham, 2000
2. Haglund C, Lindgren J, Roberts PJ, et al: Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer 60:845-851, 1989
3. Baeckstrom D, Hansson GC, Nilsson O, et al: Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J Biol Chem 266:21537-21547, 1991
4. Chari RV, Martell BA, Gross JL, et al: Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res 52:127-131, 1992
5. Chabner BA, Levine AS, Johnson BL, et al: Initial clinical trials of maytansine, an antitumor plant alkaloid. Cancer Treat Rep 62:429-433, 1978
6. Blum RH, Kahlert T: Maytansine: A phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep 62:435-438, 1978
7. Cabanillas F, Rodriguez V, Hall SW, et al: Phase I study of maytansine using a 3-day schedule. Cancer Treat Rep 62:425-428, 1978
8. Eagan RT, Ingle JN, Rubin J, et al: Early clinical study of an intermittent schedule for maytansine (NSC-153858): Brief communication. J Nat Cancer Inst 60:93-96, 1978
9. Issell BF, Crooke ST: Maytansine. Cancer Treat Rev 5:199-207, 1978
10. Liu C, Tadayoni BM, Bourret LA, et al: Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 93:8618-8623, 1996
11. Liu C, Bourret LA, Derr SM, et al: Cure of human small cell lung cancer xenografts in SCID mice by a hN901-maytansinoid immunoconjugate. Proc Annu Meet Am Assoc Cancer Res 38, 1997 (abstr 190)
12. Chari RVJ, Derr SM, Widdison WC, et al: SB 408075: A tumor activated prodrug with exceptional activity against colon, pancreatic and lung xenografts. Clin Cancer Res 5 3822s, 1999: (suppl)
13. Schwall RH, Dugger SL, Erickson SL, et al: Potent preclinical efficacy of Herceptin-DM1 against HER2-overexpressing breast tumors in vivo. Clin Cancer Res 7 3784s, 2001: (suppl)
14. Chari RVJ, Steeves RM, Xie H, et al: Preclinical development of huN901-DM1: A tumor activated prodrug directed against small cell lung cancer. Clin Cancer Res 6:4489s, 2000: (suppl)
15. Sievers EL, Larson RA, Stadtmauer EA, et al: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244-3254, 2001
16. Giles FJ, Kantarjian HM, Kornblau SM, et al: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92:406-413, 2001
17. Multani PS, O'Day S, Nadler LM, et al: Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 4:2599-2604, 1998
18. Roguska MA, Pedersen JT, Keddy CA, et al: Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA 91:969-973, 1994
19. Gelmon K, Arnold A, Verma S, et al: Pharmacokinetics and safety of trastuzumab (Herceptin) when administered every three weeks to women with metastatic breast cancer. Proc Am Assoc Clin Oncol 20:69a, 2001: (abstr 271)
20. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
21. Johnson RK, Winkler JD, Chen Y-J, et al: Immunohistochemical evidence for delivery of antibody and small molecule toxin to tumor cells in vivo following treatment of xenografts with antibody-targeted maytansinoid SB-408075. Proc Am Assoc Cancer Res 43:257, 2002
22. O'Connell MJ, Shani A, Rubin J, et al: Phase II trial of maytansine in patients with advanced colorectal carcinoma. Cancer Treat Rep 62:1237-1238, 1978
23. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002